OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis

This study evaluated the effects of combining an OX40 agonistic antibody (aOX40) with a cell vaccine targeting HER2/neu, called “Triplex”. Such HER2/neu cell vaccine included two biological adjuvants (interleukin 12 (IL12) and allogeneic histocompatibility antigens) and was previously found able to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Nanni, Patrizia, De Giovanni, Carla, Burocchi, Alessia, Nicoletti, Giordano, Landuzzi, Lorena, Palladini, Arianna, Ianzano, Marianna Lucia, Arioli, Ivano, Colombo, Mario P., Lollini, Pier-Luigi
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2018
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6136865/
https://ncbi.nlm.nih.gov/pubmed/30221061
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1465164
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados